eWellness Healthcare (EWLL) 10-Q 14 Nov 19 2019 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2019	Nov. 12, 2019
Document And Entity Information
Entity Registrant Name	eWELLNESS HEALTHCARE Corp
Entity Central Index Key	0001550020
Document Type	10-Q
Document Period End Date	Sep. 30, 2019
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		291,357,662
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2019

Consolidated Condensed Balance

Consolidated Condensed Balance Sheets (Unaudited) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
CURRENT ASSETS
Cash	$ 781,060	$ 383,335
Prepaid Expenses	380,862	95,508
Total current assets	1,161,922	478,843
Property & equipment, net	24,172	14,092
Intangible assets, net	9,500	11,000
TOTAL ASSETS	1,195,594	503,935
CURRENT LIABILITIES
Accounts payable and accrued expenses	305,825	236,741
Accounts payable - related party	630,532	684,173
Accrued expenses - related party	198,241	214,076
Accrued compensation	776,464	1,113,470
Contingent liability	90,000	90,000
Convertible debt, net of discount	2,423,293	562,362
Derivative liability	1,358,964	1,584,102
Total current liabilities	5,783,319	4,484,924
Total Liabilities	5,783,319	4,484,924
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' DEFICIT
Preferred stock, authorized, 20,000,000 shares, $.001 par value, 125,000 and 0 shares issued and outstanding, respectively	125
Common stock, authorized 1,900,000,000 shares, $.001 par value, 244,430,551 and 206,406,951 issued and outstanding, respectively outstanding, respectively	244,431	206,407
Shares to be issued	19,150
Additional paid in capital	21,173,934	17,213,838
Accumulated deficit	(26,025,365)	(21,401,234)
Total Stockholders' Deficit	(4,587,725)	(3,980,989)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 1,195,594	$ 503,935

Consolidated Condensed Balanc_2

Consolidated Condensed Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Sep. 30, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Preferred stock, shares authorized	20,000,000	20,000,000
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares issued	125,000	0
Preferred stock, shares outstanding	125,000	0
Common stock, shares authorized	1,900,000,000	1,900,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares issued	244,430,551	206,406,951
Common stock, shares outstanding	244,430,551	206,406,951

Consolidated Condensed Statemen

Consolidated Condensed Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
OPERATING EXPENSES
Executive compensation	$ 102,000	$ 102,000	$ 306,000	$ 306,000
General and administrative	709,205	322,266	1,284,556	809,704
Professional fees	669,261	407,355	1,918,402	1,360,206
Total Operating Expenses	1,480,466	831,621	3,508,958	2,475,910
Loss from Operations	(1,480,466)	(831,621)	(3,508,958)	(2,475,910)
OTHER INCOME (EXPENSE)
Interest income	13		29
Foreign exchange rate		4,507		12,598
Gain (loss) on derivative liability	1,331,213	(89,579)	1,949,180	303,898
Gain (loss) on extinguishment of debt				(43,131)
Disposal of fixed asset		(2,134)		(2,134)
Interest expense	(1,369,150)	(173,306)	(3,062,782)	(493,106)
Net Loss before Income Taxes	(1,518,750)	(1,092,133)	(4,622,531)	(2,697,785)
Income tax expense	(1,600)	(29)	(1,600)	(1,656)
Net Loss	$ (1,520,350)	$ (1,092,162)	$ (4,624,131)	$ (2,699,441)
Loss per common share
Basic	$ (0.01)	$ (0.01)	$ (0.02)	$ (0.02)
Diluted	$ (0.01)	$ (0.01)	$ (0.02)	$ (0.02)
Weighted average shares outstanding
Basic	231,454,650	174,369,861	220,916,826	158,927,170
Diluted	231,454,650	174,369,861	220,916,826	158,927,170

Reconciliation of Stockholders'

Reconciliation of Stockholders' Deficit (Unaudited) - USD ($)	Preferred Shares [Member]	Common Stock [Member]	Shares to be Issued [Member]	Additional Paid in Capital [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2017		$ 142,352		$ 13,178,131	$ (16,949,772)	$ (3,629,289)
Balance, shares at Dec. 31, 2017		142,352,406
Contributed services				55,500		55,500
Option expense				108,594		108,594
Shares issued for debt conversion		$ 3,945		209,347		213,292
Shares issued for debt conversion, shares		3,945,407
Shares issued for prepaid services		$ 800		103,200		104,000
Shares issued for prepaid services, shares		800,000
Derivative liability				219,525		219,525
Shares issued for services		$ 1,350		137,250		138,600
Shares issued for services, shares		1,350,000
Net loss					(473,973)	(473,973)
Balance at Mar. 31, 2018		$ 148,447		14,011,547	(17,423,745)	(3,263,751)
Balance, shares at Mar. 31, 2018		148,447,813
Balance at Dec. 31, 2017		$ 142,352		13,178,131	(16,949,772)	(3,629,289)
Balance, shares at Dec. 31, 2017		142,352,406
Net loss						(2,699,441)
Balance at Sep. 30, 2018		$ 181,716		16,139,737	(19,649,213)	(3,327,760)
Balance, shares at Sep. 30, 2018		181,715,991
Balance at Dec. 31, 2017		$ 142,352		13,178,131	(16,949,772)	(3,629,289)
Balance, shares at Dec. 31, 2017		142,352,406
Balance at Dec. 31, 2018		$ 206,407		17,213,838	(21,401,234)	(3,980,989)
Balance, shares at Dec. 31, 2018		206,406,951
Balance at Mar. 31, 2018		$ 148,447		14,011,547	(17,423,745)	(3,263,751)
Balance, shares at Mar. 31, 2018		148,447,813
Contributed services				55,500		55,500
Option expense				108,594		108,594
Shares issued for debt conversion		$ 13,710		622,996		636,706
Shares issued for debt conversion, shares		13,708,947
Shares issued for prepaid services		$ 1,500		103,500		105,000
Shares issued for prepaid services, shares		1,500,000
Derivative liability				154,388		154,388
Shares issued for services		$ 1,200	14,800	96,100		112,100
Shares issued for services, shares		1,200,000
Shares issued for contributions		$ 1,000		69,000		70,000
Shares issued for contributions, shares		1,000,000
Net loss					(1,133,306)	(1,133,306)
Balance at Jun. 30, 2018		$ 165,857	14,800	15,221,625	(18,557,051)	(3,151,769)
Balance, shares at Jun. 30, 2018		165,856,760
Contributed services				55,500		55,500
Option expense				142,057		142,057
Shares issued for debt conversion		$ 12,944		607,546		620,490
Shares issued for debt conversion, shares		12,943,900
Derivative liability				(49,741)		(49,741)
Shares issued for services		$ 1,325	$ (14,800)	$ 92,340		78,865
Shares issued for services, shares		1,325,000
Shares issued for financing costs		$ 1,590		$ 70,410		72,000
Shares issued for financing costs, shares		1,590,331
Net loss					(1,092,162)	(1,092,162)
Balance at Sep. 30, 2018		$ 181,716		16,139,737	(19,649,213)	(3,327,760)
Balance, shares at Sep. 30, 2018		181,715,991
Balance at Dec. 31, 2018		$ 206,407		17,213,838	(21,401,234)	(3,980,989)
Balance, shares at Dec. 31, 2018		206,406,951
Contributed services				54,000		54,000
Shares issued for debt conversion		$ 5,098		342,389		347,487
Shares issued for debt conversion, shares		5,097,255
Shares issued for prepaid services		$ 3,511		402,239		405,750
Shares issued for prepaid services, shares		3,510,870
Derivative liability				492,340		492,340
Shares issued for services		$ 1,325		180,224		181,549
Shares issued for services, shares		1,324,560
Shares issued for financing costs		$ 1,000		114,000		115,000
Shares issued for financing costs, shares		1,000,000
Net loss					(1,338,471)	(1,338,471)
Balance at Mar. 31, 2019		$ 217,341		18,799,030	(22,739,705)	(3,723,334)
Balance, shares at Mar. 31, 2019		217,339,636
Balance at Dec. 31, 2018		$ 206,407		17,213,838	(21,401,234)	(3,980,989)
Balance, shares at Dec. 31, 2018		206,406,951
Net loss						(4,624,131)
Balance at Sep. 30, 2019	$ 125	$ 244,431	19,150	21,173,934	(26,025,365)	(4,587,725)
Balance, shares at Sep. 30, 2019	125,000	244,430,551
Balance at Mar. 31, 2019		$ 217,341		18,799,030	(22,739,705)	(3,723,334)
Balance, shares at Mar. 31, 2019		217,339,636
Contributed services				54,000		54,000
Shares issued for debt conversion		$ 1,181		52,574		53,755
Shares issued for debt conversion, shares		1,181,433
Shares issued for prepaid services		$ 500		52,500		53,000
Shares issued for prepaid services, shares		500,000
Derivative liability				70,987		70,987
Shares issued for services		$ 1,650		156,434		158,084
Shares issued for services, shares		1,650,435
Shares issued for cash		$ 800		58,300		59,100
Shares issued for cash, shares		800,000
Net loss					(1,765,310)	(1,765,310)
Balance at Jun. 30, 2019		$ 221,472		19,243,825	(24,505,015)	(5,039,718)
Balance, shares at Jun. 30, 2019		221,471,504
Contributed services				54,000		54,000
Shares issued for debt conversion		$ 13,992		517,433		531,425
Shares issued for debt conversion, shares		13,991,743
Shares issued for prepaid services		$ 6,692		$ 440,769		447,461
Shares issued for prepaid services, shares		6,692,307
Derivative liability				$ 392,735		392,735
Shares issued for services		$ 2,275		150,297		152,572
Shares issued for services, shares		2,274,997
Shares issued to officers, directors and consultants	$ 125			374,875		375,000
Shares issued to officers, directors and consultants, shares	125,000
Shares to be issued for services			19,150			19,150
Net loss					(1,520,350)	(1,520,350)
Balance at Sep. 30, 2019	$ 125	$ 244,431	$ 19,150	$ 21,173,934	$ (26,025,365)	$ (4,587,725)
Balance, shares at Sep. 30, 2019	125,000	244,430,551

Consolidated Condensed Statem_2

Consolidated Condensed Statement of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Cash flows from operating activities
Net loss	$ (4,624,131)	$ (2,699,441)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	4,794	2,863
Contributed services	162,000	166,500
Shares issued for consulting services	511,355	329,565
Shares issued for financing costs	115,000	72,000
Shares issued to officers, directors and consultants	86,250
Shares issued for contribution		70,000
Options expense		359,245
Amortization of debt discount to interest expense	2,690,435	284,392
Amortization of prepaids	678,805	301,140
Foreign currency exchange		12,598
Loss on disposal of fixed asset		(2,134)
Gain on derivative liability	(1,949,180)	(303,898)
Loss on settlement of debt		43,131
Changes in operating assets and liabilities
Prepaid expense	(57,948)	(18,055)
Accounts payable and accrued expenses	111,801	194,332
Accounts payable - related party	(19,891)	287,161
Accrued expenses - related party	(15,835)	7,386
Accrued compensation	(82,006)	72,901
Net cash used in operating activities	(2,388,551)	(820,315)
Cash flows from investing activities
Purchase of equipment	(13,374)	(2,037)
Net cash used in investing activities	(13,374)	(2,037)
Cash flows from financing activities
Proceeds from issuance of common stock	59,100
Issuance of convertible debt	4,400,500	969,300
Payment on debt	(1,102,450)	(1,005)
Debt issuance costs	(577,500)	(125,150)
Net cash provided by financing activities	2,799,650	843,145
Net increase in cash	397,725	20,793
Cash, beginning of period	383,335	6,882
Cash, end of period	781,060	27,675
Cash paid for:
Taxes	1,856	1,267
Interest Expense	475,519
Non cash items:
Derivative liability and debt discount issued with new notes	2,831,539	359,732
Shares issued for debt conversion	932,667	1,190,489
Shares issued for prepaids	$ 906,211	$ 209,000

The Company

The Company	9 Months Ended
	Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
The Company	Note 1. The Company The Company and Nature of Business eWellness Healthcare Corporation (the “eWellness”, “Company”, “we”, “us”, “our”) was incorporated in the State of Nevada on April 7, 2011. The Company has generated no revenues to date. eWellness Healthcare Corporation is the first physical therapy telehealth company to offer real-time distance monitored assessments and treatments. Our business model is to have large-scale employers use our PHZIO platform as a fully PT monitored corporate musculoskeletal treatment (“MSK”) wellness program. The Company’s PHZIO home physical therapy assessment and exercise platform has been designed to disrupt the $30 billion physical therapy market, the $4 billion MSK market and the $8 billion corporate wellness industry. PHZIO re-defines the way MSK physical therapy can be delivered. PHZIO is the first real-time remote monitored 1-to-many MSK physical therapy platforms for home use. We have commenced treating patients on various commercial contracts and anticipate generating initial revenues during the 4 th Our latest challenges in the Workers Compensation space has been patient adoption of PHZIO, related to a patients’ choice to choose if they are treated in-clinic or digitally. They are nearly all choosing in-clinic care. Our pivot to address this issue was to develop and sell MSK 360 a pre-injury fitness exam and custom exercise platform that is just rolling out now. Next, we finally are getting traction for our Per-Hab product with several large TPA’s. Lastly, multiple clients are requesting an Rheumatoid Arthritis Exercise product (RA 360) that is currently being developed with a launch date of mid-January. With the success of MSK 360 we expect that more Workers Comp patients will choose digital care over in-clinic care. We have now developed four key products with large scale users that need to turn on utilization in 2020. We have a large list of corporate self-insured, TPA and insurance company sales book that we are actively focused on selling to them our MSK-360 and Pre-Hab platforms. We expect good traction from many of these firms in 2020. These products are: + PHZIO: Realtime PT monitored Digital PT Treatments (post-injury) + MSK 360: Digital “PHZIOFIT" fitness exam and customer exercise plans for employees, (pre-injury) + Pre-Hab: Digital pre-surgery (non-monitored) for Total Knee, Hip and Shoulder surgery (post injury and pre-surgery) + RA 360: (Available January 2020) Rheumatoid Arthritis Exercise Plan

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2. Summary of Significant Accounting Policies Basis of Presentation The accompanying unaudited condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial statements. Accordingly, they omit or condense notes and certain other information normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles. The accounting policies followed for quarterly financial reporting conform with the accounting policies disclosed in Note 2 to the Notes to Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2018. In the opinion of management, all adjustments necessary for a fair presentation of the financial information for the interim periods reported have been made. All such adjustments are of a normal recurring nature. The results of operations for the nine months ended September 30, 2019 are not necessarily indicative of the results that can be expected for the fiscal year ending December 31, 2019. The unaudited condensed financial statements should be read in conjunction with the financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2018. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from these good faith estimates and judgments. Going Concern For the nine months ended September 30, 2019, the Company had no revenues. The Company has an accumulated loss of $26,025,365. In view of these matters, there is substantial doubt about the Company’s ability to continue as a going concern. The Company’s ability to continue operations is dependent upon the Company’s ability to raise additional capital and to ultimately achieve sustainable revenues and profitable operations, of which there can be no guarantee. The Company intends to finance its future development activities and its working capital needs largely from the sale of public equity securities with some additional funding from other traditional financing sources, including term notes, until such time that funds provided by operations are sufficient to fund working capital requirements. The financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern. Fair Value of Financial Instruments As of September 30, 2019, the Company had the following assets and liabilities measured at fair value on a recurring basis. Total Level 1 Level 2 Level 3 Derivative Liability $ 1,358,964 $ - $ - $ 1,358,964 Total Liabilities measured at fair value $ 1,358,964 $ - $ - $ 1,358,964 As of December 31, 2018, the Company had the following assets and liabilities measured at fair value on a recurring basis. Total Level 1 Level 2 Level 3 Derivative Liability $ 1,584,102 $ - $ - $ 1,584,102 Total Liabilities measured at fair value $ 1,584,102 $ - $ - $ 1,584,102

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2019
Related Party Transactions [Abstract]
Related Party Transactions	Note 3. Related Party Transactions In November 2016, the Company signed an agreement with a programming company (“PC”) within which one of the Company’s directors and Chief Technical Officer is the Chief Marketing Officer. The agreement is for additional features to be programmed for the launch of the PHZIO platform. The Company is to pay a monthly base fee of $100,000 for the development and compensation for the Company’s CEO and CTO. Following payment of the initial $100,000, the Company is obligated to only pay $50,000 monthly until the PC has successfully signed and collected the first monthly service fee for 100 physical therapy clinics to use the PHZIO platform. The agreement establishes that the Company is indebted to the PC for $225,000 for past programming services. For this amount, the Company issued 25,280,899 common shares at a value of $0.0089 per share on April 1, 2017. The PC will also have the right to appoint 40% of the directors. At the end of September 30, 2019, the Company had a payable of $627,832 due to this company. Throughout the nine months ended September 30, 2019, the officers and directors of the Company incurred business expenses on behalf of the Company. The amounts payable to the officers as of September 30, 2019 and December 31, 2018 were $44,991 and $3,076, respectively. There were no expenses due to the board members, but the Company has accrued directors’ fees of $153,250 and $211,000 at September 30, 2019 and December 31, 2018, respectively. Because the Company is not yet profitable the officers have agreed to defer compensation. The Company had accrued executive compensation of $776,464 and $1,113,470 at September 30, 2019 and December 31, 2018 respectively.

Convertible Notes Payable

Convertible Notes Payable	9 Months Ended
	Sep. 30, 2019
Debt Disclosure [Abstract]
Convertible Notes Payable	Note 4. Convertible Notes Payable Nine Months Ended September 30, 2019 On January 29, 2019, the Company received the third tranche of $60,000 relating to a note executed on July 13, 2018. During the nine months ending September 30, 2019, the Company accrued interest expense of $1,350. On July 12, 2019, the Company prepaid this note of $60,000 plus accrued interest and a prepayment penalty of $30,000. At September 30, 2019, this note is fully paid. On January 8, 2019, the Company executed an 8% Convertible Promissory Notes payable to an institutional investor in the principal amount of $308,000. The note, which is due on January 8, 2020, has an original issue discount of $28,000 and transaction costs of $10,000. The convertible note converts into common stock of the Company at a conversion price that shall be equal to the 70% of the average of the two lowest per share trading prices for the twenty (20) trading days prior to the conversion date. During the nine months ended September 30, 2019, the Company accrued interest expense of $17,547. During the nine months ended September 30, 2019, the investor converted $30,000 of principal and $1,687 of accrued interest for 905,333 shares of common stock at a price of $.035. At September 30, 2019, there is $278,000 principal outstanding. On January 8, 2019, the Company executed an 8% Convertible Promissory Notes payable to an institutional investor in the principal amount of $308,000 each. The note, which is due on January 8, 2020, has an original issue discount of $28,000 and transaction costs of $10,000. The convertible note converts into common stock of the Company at a conversion price that shall be equal to the 70% of the average of the two lowest per share trading prices for the twenty (20) trading days prior to the conversion date. During the nine months ended September 30, 2019, the Company accrued interest expense of $17,029. During the nine months ended September 30, 2019, the investor converted $162,000 of principal for 4,424,400 shares of common stock for prices ranging from $.035 to $.042. At September 30, 2019, there is $146,000 principal outstanding. On January 9, 2019, the Company executed a 12% Convertible Promissory Note payable to an institutional investor in the principal amount of $114,000. The note, which is due on October 30, 2019, has an original issue discount of $11,000 and transaction costs of $3,000. The convertible note converts into common stock of the Company at a conversion price that shall be equal to the 70% average of the two lowest per share trading prices for the ten (10) trading days prior to the conversion date. During the nine months ended September 30, 2019, the Company accrued interest expense of $6,028. On July 12, 2019, the Company prepaid this note of $114,000 plus accrued interest and a prepayment penalty of $42,010. At September 30, 2019, this note is fully paid. On January 29, 2019, the Company executed a 12% Convertible Promissory Note payable to an institutional investor in the principal amount of $58,300. The note, which is due on November 15, 2019, has an original issue discount of $5,300 and transaction costs of $3,000. The convertible note converts into common stock of the Company at a conversion price that shall be equal to the 70% average of the two lowest per share trading prices for the ten (10) trading days prior to the conversion date. During the nine months ended September 30, 2019, the Company accrued interest of $2,753. On July 12, 2019, the Company prepaid this note of $58,300 plus accrued interest and a prepayment penalty of $21,369. At September 30, 2019, this note is fully paid. On February 22, 2019, the Company received the fourth tranche of $30,000 relating to a note executed on July 13, 2018. During the nine months ending September 30, 2019, the Company accrued interest of $534. On September 17, 2019, the convertible debt holder converted $9,700 of principal for 340,000 shares of common stock at a price of $.03. At September 30, 2019, there is $20,300 principal outstanding. On March 18, 2019, the Company executed a Securities Purchase Agreement for Convertible Debentures to an institutional investor in the principal amount of $365,000 to be funded in six tranches: $65,000 at signing, $100,000 forty-five (45) days after the signing date and $200,000 forty-five (45) days after the second closing date. The debentures, which are payable on March 18, 2022, have a 10% original issue discount and a commitment fee of $5,000 payable with the signing debenture. The debentures convert into common stock of the Company at a conversion price equal to the lesser of (i) $.12 or (ii) seventy percent (70%) of the lowest traded price (as reported by Bloomberg LP) of the common stock for the ten (10) trading days prior to the conversion date. The first tranche of $65,000 was received on March 21, 2019. On September 12, 2019, the Company prepaid this note of $65,000 and a prepayment penalty of $19,500. At September 30, 2019, this note is fully paid. On March 18, 2019, the Company executed a 12% Convertible Promissory Note payable to an institutional investor in the principal amount of $47,300. The note, which is payable on January 30, 2020, has an original issue discount of $4,300 and transaction costs of $3,000. The convertible note converts into common stock of the Company at a conversion price equal to 70% of the average of the lowest two (2) trading prices during the ten (10) trading day period ending on the last complete trading day prior to the conversion date. During the nine months ended September 30, 2019, the Company accrued interest expense of $3,226. On September 12, 2019, the Company prepaid this note of $47,300 plus accrued interest and a prepayment penalty of $16,555. At September 30, 2019, this note is fully paid. On March 21, 2019, the Company executed a 3% Convertible Promissory Note payable to an institutional investor in the principal amount of $360,000. The note, which is payable twelve (12) months after each tranche is funded, has an original issue discount of $60,000. The original issue discount will be prorated with each tranche paid. The first tranche of $60,000 is due at signing date. The convertible note converts into common stock of the Company at a conversion price that shall be equal to 65% of the lesser of (i) lowest trading price or (ii) the lowest closing bid price on the OTCQB during the twenty-five (25) trading day period ending on the last complete trading day prior to the conversion date. The first tranche was received on March 29, 2019. The second tranche of $37,500 was received on July 19, 2019. During the nine months ended September 30, 2019, the Company accrued interest expense of $2,925. On September 30, 2019, the Company prepaid the first tranche of $60,000 plus accrued interest and a prepayment penalty of $30,000. At September 30, 2019, only the second tranche of $37,500 is outstanding. On March 21, 2019, the Company executed a 12% Convertible Promissory Note to an institutional investor in the principal amount of $1,500,000 to be funded over separate tranches; the first tranche to be funded on signing. The note, which is due and payable six (6) months after the funding date of each tranche, has an original issue discount of 10%. The Company issued 3,260,870 shares of restricted common stock on the closing date. These are deemed returnable shares which the investor must return if the Company repays the note prior to the maturity date. In addition, the Company issued 1,000,000 shares of restricted common stock as a commitment fee. The convertible note converts into common stock of the Company at a conversion price that shall be equal to 65% of the lowest trading price during the thirty (30) day trading period ending on the last complete trading day prior to the conversion date. The first tranche of $750,000 was received on March 25, 2019. The second tranche of $350,000 was received on July 12, 2019 and the Company issued 2,692,307 shares of restricted common stock. These shares are redeemable if the Company pays the note prior to the maturity date of January 20, 2020. The third and final tranche was received on September 9, 2019 and the Company issued 4,000,000 shares of restricted common stock. These shares are redeemable if the Company pays the note prior to the maturity date of March 12, 2020. During the nine months ended September 30, 2019, the Company accrued interest expense of $57,337. On April 1, 2019, the Company executed a 12% Convertible Promissory Note payable to an institutional investor in the principal amount of $58,300. The note, which is payable on February 15, 2020, has an original issue discount of $5,300 and transaction costs of $3,000. The convertible note converts into common stock of the Company at a conversion price equal to 70% of the average of the lowest two (2) trading prices during the ten (10) trading day period ending on the last complete trading day prior to the conversion date. During the nine months ended September 30, 2019, the Company accrued interest of $3,811. On September 12, 2019, the Company prepaid this note of $58,300 plus accrued interest and a prepayment penalty of $20,405. At September 30, 2019, this note is fully paid. On May 6, 2019, the Company executed a convertible note conversion period extension agreement on a note dated October 28, 2018, within which the period of conversion by note holder was extended to May 27, 2019. The Company paid $16,031 to note holder for this extension agreement. On May 28, 2019, the Company executed a second extension agreement on this note within which the period of conversion by note holder was extended to June 11, 2019. The Company paid $16,105 to note holder for this extension agreement. During the nine months ended September 30, 2019, the note holder converted the $308,000 note and accrued interest of $16,337 into 8,987,253 shares of common shares at prices ranging from $.035 $.04508. At September 30, 2019, this note has been fully converted. On May 13, 2019, the Company executed a 12% Convertible Promissory Note payable to an institutional investor in the principal amount of $110,000. The note, which is due on February 13, 2020, has an original issue discount of $10,000 and transactions costs of $3,000. The convertible note converts into common stock of the Company at conversion price that shall be equal to the 65% of the lowest closing price for the twenty (20) trading days prior to the conversion date. During the nine months ended September 30, 2019, the Company accrued interest expense of $5,063. On July 2, 2019, two Back-End notes executed in October 2018 with an institutional investor was funded for $154,000 each. Each note, which is due on October 29, 2019, has an original issue discount of $16,500. The convertible notes convert into common stock of the Company at conversion price that shall be equal to the 70% of the average of the two (2) lowest per share trading prices for the prior twenty (20) trading days including the conversion date. During the nine months ended September 30, 2019, the Company accrued interest expense of $3,038 for each note. On July 5, 2019, the Company signed an amendment to a convertible note issued on March 21, 2019 revising the conversion price from 75% to 65% of the lowest trading price during the thirty (30) trading days prior to the conversion date. On July 8, 2019, the Company executed a 12% Convertible Promissory Note payable to an institutional investor in the principal amount of $140,800. The note, which is payable on April 30, 2020, has an original issue discount of $12,800 and transaction costs of $3,000. The convertible note converts into common stock of the Company at a conversion price equal to 70% of the average of the lowest two (2) trading prices during the ten (10) trading day period ending on the last complete trading day prior to the conversion date. During the nine months ended September 30, 2019, the Company accrued interest of $3.379. On July 8, 2019, the Company executed a convertible note conversion period extension agreement on a note dated January 8, 2019 within which the period of conversion by note holder was extended to August 9, 2019. The Company paid $21,560 to note holder for this extension agreement. On July 9, 2019, the Company executed a 12% Convertible Promissory Note payable to an institutional investor in the principal amount of $113,000. The note, which is due on July 9, 2020, has an original issue discount of $10,000 and transaction costs of $3,000. The convertible note converts into common stock of the Company at a conversion price that shall be equal to the 65% average of the lowest per share trading prices for the twenty (20) trading days prior to the conversion date. During the nine months ended September 30, 2019, the Company accrued interest expense of $2,712. On July 9, 2019, the Company executed an 8% Convertible Promissory Note payable to an institutional investor in the principal amount of $235,000. The note, which is due on July 11, 2020, has an original issue discount of $25,200 and transaction costs of $10,000. The convertible note converts into common stock of the Company at a conversion price that shall be equal to the 65% average of the lowest per share trading prices for the prior twenty (20) trading days including the conversion date. During the nine months ended September 30, 2019, the Company accrued interest expense of $3,605. On July 10, 2019, the Company executed a convertible note conversion period extension agreement on a note dated January 8, 2019 within which the period of conversion by note holder was extended to August 9, 2019. The Company paid $22,410 to note holder for this extension agreement. On July 11, 2019, the Company executed a 12% Convertible Promissory Note payable to an institutional investor in the principal amount of $250,000. The note, which is due on April 19, 2020, has an original issue discount of $37,500 and transaction costs of $5,000. The convertible note converts into common stock of the Company at a conversion price that shall be equal to 65% of the average of the lowest per share trading prices for the twenty-five (25) trading days prior to the conversion date. During the nine months ended September 30, 2019, the Company accrued interest expense of $5,425. On July 30, 2019, the Company executed two 12% Convertible Promissory Notes payable to two institutional investors in the principal amount of $38,500 each. Each note, which is due on April 30, 2020, has an original issue discount of $3,500 and transaction costs of $1,500. The convertible notes convert into common stock of the Company at a conversion price that shall be equal to the 65% of the lowest per share trading prices for the twenty (20) trading days prior to the conversion date. During the nine months ended September 30, 2019, the Company accrued interest expense of $1,380 for the two notes. On September 4, 2019, the Company executed a 12% Convertible Promissory Note payable to an institutional investor in the principal amount of $58,300. The note, which is payable on July 15, 2020, has an original issue discount of $5,300 and transaction costs of $3,000. The convertible note converts into common stock of the Company at a conversion price equal to 70% of the average of the lowest two (2) trading prices during the ten (10) trading day period ending on the last complete trading day prior to the conversion date. During the nine months ended September 30, 2019, the Company accrued interest of $364. On September 9, 2019, a Back-End note executed in January 2019 with an institutional investor was funded for $154,000. The note, which is due on January 9, 2020, has an original issue discount of $14,000 and transaction costs of $5,000. The convertible note converts into common stock of the Company at conversion price that shall be equal to the 70% of the average of the two (2) lowest per share trading prices for the twenty (20) trading days prior to the conversion date. During the nine months ended September 30, 2019, the Company accrued interest expense of $641. On September 19, 2019, two Back-End notes executed in January 2019 with an institutional investor was funded for $154,000 each. Each note, which is due on January 8, 2020, has an original issue discount of $14,000 and transactions costs of $5,000. The convertible notes convert into common stock of the Company at conversion price that shall be equal to the 70% of the average of the two (2) lowest per share trading prices for the prior twenty (20) trading days including the conversion date. During the nine months ended September 30, 2019, the Company accrued interest expense of $371 for each note. Year Ended December 31, 2018 In January 2018, the Company executed an 8% Convertible Promissory Note payable to an institutional investor in the principal amount of $110,000. During the year ended December 31, 2018, the note, which was due on October 12, 2018, and accrued interest totaling $4,489 was fully converted into 2,412,827 shares of common stock at a price of $.04745 per share. In January 2018, the Company executed an 12% Convertible Promissory Note payable to an institutional investor in the principal amount of $91,300. During the year ended December 31, 2018, the note, which was due on October 30, 2018, and accrued interest totaling $4,980 was fully converted into 1,630,799 shares of common stock at prices ranging from $.0583 to $.0603. In February 2018, the Company executed an 12% Convertible Promissory Note payable to an institutional investor in the principal amount of $63,800. During year ended December 31, 2018, the note, which was due on November 30, 2018, and accrued interest totaling $3,480 was fully converted into 1,309,799 shares of common stock at prices ranging from $.0487 to $.0532. In March 2018, the Company executed an 8% Convertible Promissory Note payable to an institutional investor in the principal amount of $77,000. As of September 30, 2018, the institutional investor exercised its MFN provision in Paragraph 4a increasing the OID from the stated in the note from 10% to 15% thus increasing the amount owed to $80,500. During the year ended December 31, 2018, the note, which was due on December 5, 2018, and accrued interest totaling $5,928 was fully converted into 2,402,436 shares of common stock at a price of $.036. In March 2018, the Company executed an 12% Convertible Promissory Note payable to an institutional investor in the principal amount of $72,450. During the year ended December 31, 2018, the note, which was due on December 30, 2018, and accrued interest totaling $3,780 was fully converted into 1,877,796 shares of common stock at prices ranging from $.0393 to $.0437. In May 2018, the Company executed an 8% Convertible Promissory Note payable to an institutional investor in the principal amount of $125,000. During the year ended December 31, 2018, the note, which is due on May 10, 2019, and accrued interest totaling $415 was fully converted into 1,626,268 shares of common stock at prices ranging from $.0628 to $.1032. At the year ended December 31, 2018, the Company is still liable for $5,288 of accrued interest that has not yet been converted. In May 2018, the Company executed an 12% Convertible Promissory Note payable to an institutional investor in the principal amount of $51,750. During the year ended December 31, 2018, the note, which is due on March 1, 2019, and accrued interest of $2,700 was fully converted into 658,722 shares of common stock at prices ranging from $.081 and $.085. In July 2018, the Company executed an 12% Convertible Promissory Note payable to an institutional investor in the principal amount of $56,500. The note, which is due on April 17, 2019, has an original issue discount of $6,500. The convertible notes convert into common stock of the Company at conversion price that shall be equal to the lesser of: (i) $0.21 or (ii) 75% of the lowest per share trading price for the thirty (30) trading days before the issued date of this note. The Company issued 100,000 shares of common stock valued at $8,000 upon the execution of this note. During the year ended December 31, 2018, the Company recognized interest expense of $2,991. In July 2018, the Company executed an 3% Convertible Promissory Note payable to an institutional investor in the principal amount of $180,000 for funding in six tranches. The note, which is due twelve months from the date of each individual tranche, has an original issue discount of $10,000 per tranche. The convertible notes convert into common stock of the Company at conversion price that shall be equal to 75% of the market price which is lowest trading price during the twenty (20) trading day period ending on the last complete trading day prior to the conversion date. The trading price is the lesser of: (i) lowest traded price or (ii) the lowest closing bid price on the OTCQB. The first tranche of $60,000 was received in the month of July and second tranche of $30,000 was received in the month of August. During the year ended December 31, 2018, the Company recognized interest expense of $1,102. In July 2018, the Company executed an 12% Convertible Promissory Note payable to an institutional investor in the principal amount of $28,250. The note, which is due on April 17, 2019, has an original issue discount of $3,250. The convertible notes convert into common stock of the Company at conversion price that shall be equal to the lesser of: (i) $0.21 or (ii) 75% of the lowest per share trading price for the thirty (30) trading days before the issued date of this note. The Company issued 50,000 shares of common stock valued at $4,000 upon the execution of this note. During the year ended December 31, 2018, the Company recognized interest expense of $1,495. In July 2018, the Company executed an 12% Convertible Promissory Note payable to an institutional investor in the principal amount of $77,000. As of September 30, 2018, the institutional investor exercised its MFN provision in Paragraph 4a increasing the OID from the stated in the note from 10% to 15% thus increasing the amount owed to $80,500. The note, which is due on April 5, 2019, has an original issue discount of $7,000. The convertible notes convert into common stock of the Company at conversion price that shall be equal to the lesser of: (i) $0.06 or (ii) 75% of the lowest per share trading price for the ten (10) trading days before the conversion date. During the year ended December 31, 2018, the Company recognized interest expense of $4,870. In July 2018, the Company executed an 12% Convertible Promissory Note payable to an institutional investor in the principal amount of $60,950. The note, which is due on April 30, 2019, has an original issue discount of $7,950. The convertible notes convert into common stock of the Company at conversion price that shall be equal to the lesser of: (i) $.20 or (ii) variable conversion price which is 75% of the average of the lowest (2) VWAP for the ten (10) trading day period ending on the latest compete trading day prior to the conversion date. During the year ended December 31, 2018, the Company recognized interest expense of $3,647. In August 2018, the Company executed an 12% Convertible Promissory Note payable to an institutional investor in the principal amount of $58,300. The note, which is due on June 15, 2019, has an original issue discount of $5,300. The convertible notes convert into common stock of the Company at conversion price that shall be equal to the lesser of: (i) $.20 or (ii) variable conversion price which is 75% of the average of the two (2) lowest VWAP for the ten (10) trading day period ending on the latest compete trading day prior to the conversion date. During the year ended December 31, 2018, the Company recognized interest expense of $2,338. In October 2018, the Company executed an 12% Convertible Promissory Note payable to an institutional investor in the principal amount of $47,300. The note, which is due on July 15, 2019, has an original issue discount of $7,300. The convertible notes convert into common stock of the Company at conversion price that shall be equal to the variable conversion price which is 70% of the average of the two (2) lowest VWAP for the ten(10) trading day period ending on the latest compete trading day prior to the conversion date. During the year ended December 31, 2018, the Company recognized interest expense of $1,291. In October 2018, the Company executed an 8% Convertible Promissory Note payable to an institutional investor in the principal amount of $165,000. The note, which is due on October 12, 2019, has an original issue discount of $15,000. The convertible notes convert into common stock of the Company at conversion price that shall be equal to 65% of the lowest per share closing price during the fifteen (15) trading days immediately preceding the date of the notice of conversion. The first tranche of $110,000 was received in the month of October and the second tranche of $55,000 was received in the month of November. During the year ended December 31, 2018, the Company recognized interest expense of $2,594. In October 2018, the Company executed two 8% Convertible Promissory Notes payable to two institutional investors, each in the principal amount of $308,000. Each note, which is due on October 29, 2019, has an original issue discount of $33,000. The convertible notes convert into common stock of the Company at conversion price that shall be equal to the 70% of the average of the two (2) lowest per share trading prices for the twenty (20) trading days prior to the conversion date. During the year ended December 31, 2018, the Company recognized interest expense of $4,118 for each note. In November 2018, a Back-End note executed in May 2018 with an institutional investor was funded. The Back-End note is an 8% Convertible Promissory Note payable in the principal amount of $125,000. The note, which is due on May 10, 2019, has an original issue discount of $10,000. The convertible notes convert into common stock of the Company at conversion price that shall be equal to 72% of the lowest VWAP for the ten (10) trading days prior to and including the conversion date. Conversion into shares of common stock can commence following the 180 th

Equity Transactions

Equity Transactions	9 Months Ended
	Sep. 30, 2019
Equity [Abstract]
Equity Transactions	Note 5. Equity Transactions Preferred Stock The total number of shares of preferred stock which the Company shall have authority to issue is 20,000,000 shares with a par value of $0.001 per share. During the nine months ended September 30, 2019, the Company authorized the issuance of 1,000,000 shares of preferred stock to officers, directors and consultants as deferred compensation and/or expense. The shares are eligible for conversion after 24 months into 40 shares of common stock per each preferred share. The value of the issued shares was calculated on the basis of 40 shares per preferred share at the common share value on the date of issuance. The deferred compensation value of the shares will vest monthly at 1/24 th Common Stock On July 9, 2019, the Company filed a Definitive Information Statement on Schedule 14C for the purpose of authorizing the increase in the number of authorized shares of Common Stock from four hundred million (400,000,000) shares of Common Stock to nine hundred million (900,000,000) shares of Common Stock (the “Authorized Common Stock Share Increase”). On July 9, 2019, the Company filed Articles of Amendment to the Company’s Articles of Incorporation to implement the Authorized Common Stock Share Increase with the State of Nevada. On October 10, 2019, the Company filed a Definitive Information Statement on Schedule 14C for the purpose of authorizing the increase in the number of authorized shares of Common Stock from nine hundred million (900,000,000) shares of Common Stock to one billion nine hundred million (1,900,000,000) shares of Common Stock (the “Authorized Common Stock Share Increase”). On October 15, 2019, the Company filed Articles of Amendment to the Company’s Articles of Incorporation to implement the Authorized Common Stock Share Increase with the State of Nevada. Nine Months Ended September 30, 2019 On February 7, 2019, the Company executed an amendment to a contract executed on April 8, 2018 for twelve months for consulting services. The Company issued 250,000 shares of common stock at the signing of the contract valued at $30,500 that is being amortized over the life of the contract. On March 22, 2019, the Company issued 3,260,870 shares of common stock to an institutional investor as part of a promissory note for the first tranche payment. These shares are returnable if the Company repays the promissory note before the maturity date. The value of these shares is $375,000 which was recorded as prepaid until the six-month maturity has passed. The Company also issued 1,000,000 shares of common stock to the institutional investor as a commitment fee. The value of these shares is $115,000. On April 2, 2019, the Company issued 800,000 shares of common stock pursuant to a capital call notice in relation to an Equity Purchase Agreement dated June 18, 2018. The capital call totaled $59,100. On May 17, 2019, the Company executed a contract for three months for consulting services. The Company issued 500,000 shares of common stock at the signing of the contract valued at $53,000 that is being amortized over the life of the contract. The contract further indicated that another 500,000 shares were to be issued at the end of three months. The Company issued the second 500,000 shares of common stock on August 20, 2019. The value of the shares is $31,200 and was expensed. On July 10, 2019, the Company issued 2,692,307 shares of common stock to an institutional investor as part of a promissory note for the second tranche payment. These shares are returnable if the Company repays the promissory note before the maturity date. The value of these shares is $167,462 which was recorded as prepaid until the six-month maturity has passed. On September 30, 2019, the Company issued 4,000,000 shares of common stock to an institutional investor as part of a promissory note for the third and final tranche payment. These shares are returnable if the Company repays the promissory note before the maturity date. The value of these shares is $280,000 which was recorded as prepaid until the six-month maturity has passed. On September 25, 2019, the Company executed a contract for six months for consulting services. The contract included the issuance of 250,000 shares of common stock. The value of these shares is $13,750. The shares had not yet been issued at the nine months ended September 30,2019, so the value was recorded as Shares to be Issued. During the nine months ended September 30, 2019, the Company issued 4,749,992 shares of common stock to consultants for services rendered in accordance to consulting agreements. The value of these shares is $466,403 During the nine months ended September 30, 2019, the Company issued 20,270,431 shares of common stock for debt conversion totaling $932,667 which includes $889,950 principal, $40,217 accrued interest and $2,500 due diligence fee. Nine Months Ended September 30, 2018 In January 2018, the Board of Directors approved the extension of an Advisory Agreement dated February 15, 2015 for one year. The Company issued 800,000 shares of common stock as compensation with a value of $104,000. This value is being amortized over the life of the contract. During the nine months ended September 30, 2018, the Company issued a total of 26,598,252 shares of common stock per debt conversion of convertible notes. The total of the debt conversion was $1,190,189 which includes $163,157 of accrued interest. During the nine months ended September 30, 2018, the Company issued 3,875,000 shares of common stock for marketing and consulting services valued at $329,565. During the nine months ended September 30, 2018, the Company issued 4,000,000 shares of common stock for settlement of a complaint filed in the United States Federal District Count (see Footnote 4). The debt settled totaled $236,868 which includes $56,817 of accrued interest. During the nine months ended September 30, 2018, the Company issued 1,590,331 shares of common stock for financing fees for convertible debt issued. These shares were valued at $72,000. In June 2018, the Company entered into a consulting agreement within which the Company agreed to issue 125,000 shares of common stock per month beginning in July 2018 and 1,500,000 shares of common stock upon signing of the agreement. The 1,500,000 shares of common stock were issued with a value of $105,000 which is being amortized over the life of the contract. In June 2018, the Company executed an Equity Purchase Agreement with an institutional investor within which the investor agrees to purchase up to $1,500,000 of the Company’s common stock, par value $0.001. As an inducement to the investor to enter into the agreement, the Company issued 1,000,000 restricted shares of common stock to the investor valued at $70,000. In January 2018, the Board of Directors agreed to form a new eWellness Healthcare Corporation 2018 Equity Incentive Plan (“Plan”). The Plan shall be for 20,000,000 shares of common stock that will be placed in a 10b5-1 Sales Plan that will be registered under an S-8 Registration Statement. Under the sales plan, each recipient will open an account with Garden State Securities (“GSS”) for management of all sales of shares issued under the Plan. Quarterly limitations are placed on the number of shares that can be sold. The Company initially allocated 17,400,000 shares to officers, directors and consultants. As of September 30, 2018, no shares were issued. Stock Options The following is a summary of the status of all Company’s stock options as of September 30, 2019 and changes during the nine months ended on that date: Weighted Number Average Remaining Intrinsic Options Price Life (yrs) Value Outstanding at December 31, 2018 2,850,000 $ 0.80 2.2 $ - Granted - - Exercised - - Cancelled - - Outstanding at September 30, 2019 2,850,000 0.80 1.4 $ - Options exercisable at September 30, 2019 2,850,000 $ 0.80 1.4 $ - The Company recognized stock option expense of $0 and $217,188 for the nine months ended September 30, 2019 and 2018, respectively. Warrants In March 2018, the Board of Directors, at the request and with the approval of the investors, determined that it was in the best interests of the Company and the Investors, based upon market price and relatively limited liquidity of the shares of common stock that the Company revised the expiration date and exercise price for 417,429 unexercised warrants granted on April 9, 2015. The original expiration date of April 9, 2018 was extended to April 9, 2019. During the nine months ended September 30, 2019, these warrants expired. The following is a summary of the status of the Company’s warrants as of September 30, 2019 and changes during the nine months ended on that date: Weighted Number of Average Remaining Intrinsic Warrants Price Life (yrs.) Value Outstanding at December 31, 2018 3,778,179 $ 0.48 1.4 $ - Granted - - - - Exercised - - - - Cancelled 477,429 - - - Outstanding at September 30, 2019 3,300,750 $ 0.52 1.1 $ 22.240 Warrants exercisable at September 30, 2019 3,300,750 $ 0.52 1.1 $ 22,240

Commitments, Contingencies

Commitments, Contingencies	9 Months Ended
	Sep. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments, Contingencies	Note 6. Commitments, Contingencies The Company may be subject to lawsuits, administrative proceedings, regulatory reviews or investigations associated with its business and other matters arising in the normal conduct of its business. The following is a description of an uncertainty that is considered other than ordinary, routine and incidental to the business. The closing of the Initial Exchange Agreement with Private Co. was conditioned upon certain, limited customary representations and warranties, as well as, among other things, our compliance with Rule 419 (“Rule 419”) of Regulation C under the Securities Act of 1933, as amended (the “Securities Act”) and the consent of our shareholders as required under Rule 419. Accordingly, we conducted a “Blank Check” offering subject to Rule 419 (the “Rule 419 Offering”) and filed a Registration Statement on Form S-1 to register the shares of such offering; the Registration Statement was declared effective on September 14, 2012. We used 10% of the subscription proceeds as permitted under Rule 419 and the amount remaining in the escrow trust as of the date of the closing of the Share Exchange was $90,000 (the “Trust Account Balance”). Rule 419 required that the Share Exchange occur on or before March 18, 2014, but due to normal negotiations regarding the transactions and the parties’ efforts to satisfy all the closing conditions, the Share Exchange did not close on such date. Accordingly, after numerous discussions with management of both parties, they entered into an Amended and Restated Share Exchange Agreement (the “Share Exchange Agreement”) to reflect a revised business combination structure, pursuant to which we would: (i) file a registration statement on Form 8-A (“Form 8A”) to register our common stock pursuant to Section 12(g) of the Exchange Act, which we did on May 1, 2014 and (ii) seek to convert the participants of the Rule 419 Offering into participants of a similarly termed private offering (the “Converted Offering”), to be conducted pursuant to Regulation D, as promulgated under the Securities Act. Fifty-two persons participated in the Rule 419 Offering and each of them gave the Company his/her/its consent to use his/her/its escrowed funds to purchase shares of the Company’s restricted common stock in the Converted Offering (the “Consent”) rather than have their funds returned. To avoid further administrative work for the investors, we believe that we took reasonable steps to inform investors of the situation and provided them with an appropriate opportunity to maintain their investment in the Company, if they so choose, or have their funds physically returned. Management believed the steps it took constituted a constructive return of the funds and therefore met the requirements of Rule 419. However, pursuant to Rule 419(e)(2)(iv), “funds held in the escrow or trust account shall be returned by first class mail or equally prompt means to the purchaser within five business days [if the related acquisition transaction does not occur by a date that is 18 months after the effective date of the related registration statement].” As set forth above, rather than physically return the funds, we sought consent from the investors of the Rule 419 Offering to direct their escrowed funds to the Company to instead purchase shares in the Converted Offering. The consent document (which was essentially a form of rescission) was given to the investors along with a private placement memorandum describing the Converted Offering and stated that any investor who elected not to participate in the Converted Offering would get 90% of their funds physically returned. Pursuant to Rule 419(b)(2)(vi), a blank check company is entitled to use 10% of the proceed/escrowed funds; therefore, if a return of funds is required, only 90% of the proceed/escrowed funds need be returned. The Company received $100,000 proceeds and used $10,000 as per Rule 419(b)(2)(vi); therefore, only $90,000 was subject to possible return. As disclosed therein, we filed the amendments to the initial Form 8-K in response to comments from the SEC regarding the Form 8-K and many of those comments pertain to an alleged violation of Rule 419. The Company continued to provide the SEC with information and analysis as to why it believes it did not violate Rule 419 but was unable to satisfy the SEC’s concerns. Comments and communications indicate that Rule 419 requires a physical return of funds if a 419 offering cannot be completed because a business combination was not consummated within the required time frame; constructive return is not permitted. Because of these communications and past comments, we are disclosing that we did not comply with the requirements of Rule 419, which required us to physically return the funds previously submitted to escrow pursuant to the Rule 419 Offering. Because of our failure to comply with Rule 419, the SEC may bring an enforcement action or commence litigation against us for failure to strictly comply with Rule 419. If any claims or actions were to be brought against us relating to our lack of compliance with Rule 419, we could be subject to penalties (including criminal penalties), required to pay fines, make damages payments or settlement payments. In addition, any claims or actions could force us to expend significant financial resources to defend ourselves, could divert the attention of our management from our core business and could harm our reputation. Ultimately, the SEC determined to terminate its review of the Initial Form 8-K and related amendments, rather than provide us with additional opportunities to address their concerns and therefore, we did not clear their comments. It is not possible at this time to predict whether or when the SEC may initiate any proceedings, when this issue may be resolved or what, if any, penalties or other remedies may be imposed, and whether any such penalties or remedies would have a material adverse effect on our consolidated financial position, results of operations, or cash flows. Litigation and enforcement actions are inherently unpredictable, the outcome of any potential lawsuit or action is subject to significant uncertainties and, therefore, determining currently the likelihood of a loss, any SEC enforcement action and/or the measurement of the amount of any loss is complex. Consequently, we are unable to estimate the range of reasonably possible loss. Our assessment is based on an estimate and assumption that has been deemed reasonable by management, but the assessment process relies heavily on an estimate and assumption that may prove to be incomplete or inaccurate, and unanticipated events and circumstances may occur that might cause us to change that estimate and assumption. Considering the uncertainty of this issue and while Management evaluates the best and most appropriate way to resolve same, management determined to create a reserve on the Company’s Balance Sheet for the $90,000 that was subject to the Consent. From time to time the Company may become a party to litigation matters involving claims against the Company. Except as may be outlined above, the Company believes that there are no current matters that would have a material effect on the Company’s financial position or results of operations.

Derivative Valuation

Derivative Valuation	9 Months Ended
	Sep. 30, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Valuation	Note 7. Derivative Valuation The Company evaluated the convertible debentures and associated warrants in accordance with ASC Topic 815, “Derivatives and Hedging,” and determined that the conversion feature of the convertible promissory notes was not afforded the exemption for conventional convertible instruments due to their variable conversion rates. The notes have no explicit limit on the number of shares issuable, so they did not meet the conditions set forth in current accounting standards for equity classification. Therefore, these have been characterized as derivative instruments. We elected to recognize the notes under ASU paragraph 815-15-25-4, whereby there would be a separation into a host contract and derivative instrument. We elected to initially and subsequently measure the notes and warrants in their entirety at fair value, with changes in fair value recognized in earnings. The debt discount is amortized over the life of the note and recognized as interest expense. For the nine months ended September 30, 2019 and 2018, the Company amortized the debt discount of $2,690,435 and $284,390, respectively. During the nine months ended September 30, 2019, the Company had the following activity in the derivative liability account: Notes Warrants Total Derivative liability at December 31, 2018 $ 1,402,721 $ 181,381 $ 1,584,102 Addition of new conversion option derivatives 3,631,177 - 3,631,177 Conversion of note derivatives (1,107,498 ) - (1,107,498 ) Change in fair value (2,582,681 ) (166,137 ) (2,748,818 ) Derivative liability at September 30, 2019 $ 1,343,719 $ 15,244 $ 1,358,963 For purposes of determining the fair market value of the derivative liability, the Company used Black Scholes option valuation model. The significant assumptions used in the Black Scholes valuation of the derivative are as follows: Stock price at valuation date $ .03-.10 Exercise price of warrants $ .25 Conversion rate of convertible debt $ .445 Risk free interest rate 1.6%-2.42 % Stock volatility factor 102.5%-190 % Years to Maturity .06 – 2.72 Expected dividend yield None

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2019
Subsequent Events [Abstract]
Subsequent Events	Note 8. Subsequent Events On October 2, 2019, the Company executed a 10% Convertible Promissory Note payable to an institutional investor in the principal amount of $57,750. The note, which is payable on October 2, 2020, has an original issue discount of $5,250 and transaction costs of $2,500. The convertible note converts into common stock of the Company at a conversion price equal to 65% of the lowest trading prices during the twenty (20) trading day period ending on the last complete trading day prior to the conversion date. On October 10, 2019, the Company filed a Definitive Information Statement on Schedule 14C for the purpose of authorizing the increase in the number of authorized shares of Common Stock from nine hundred million (900,000,000) shares of Common Stock to one billion nine hundred million (1,900,000,000) shares of Common Stock (the “Authorized Common Stock Share Increase”). On October 15, 2019, the Company filed Articles of Amendment to the Company’s Articles of Incorporation to implement the Authorized Common Stock Share Increase with the State of Nevada. From October 1 until the filing of this report, the Company issued 374,999 shares of common stock per consulting agreements valued at $12,150. From October 1 until the filing of this report, the Company issued 45,502,112 shares of common stock for convertible debt conversion totaling $508,655 which includes $436,906 principal, $69,199 accrued interest and $2,550 financing costs From October 1 until the filing of this report, the Company issued 1,050,000 shares of common stock for prepaid services valued at $39,750 which is being amortized over the life of the contracts.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial statements. Accordingly, they omit or condense notes and certain other information normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles. The accounting policies followed for quarterly financial reporting conform with the accounting policies disclosed in Note 2 to the Notes to Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2018. In the opinion of management, all adjustments necessary for a fair presentation of the financial information for the interim periods reported have been made. All such adjustments are of a normal recurring nature. The results of operations for the nine months ended September 30, 2019 are not necessarily indicative of the results that can be expected for the fiscal year ending December 31, 2019. The unaudited condensed financial statements should be read in conjunction with the financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2018.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from these good faith estimates and judgments.
Going Concern	Going Concern For the nine months ended September 30, 2019, the Company had no revenues. The Company has an accumulated loss of $26,025,365. In view of these matters, there is substantial doubt about the Company’s ability to continue as a going concern. The Company’s ability to continue operations is dependent upon the Company’s ability to raise additional capital and to ultimately achieve sustainable revenues and profitable operations, of which there can be no guarantee. The Company intends to finance its future development activities and its working capital needs largely from the sale of public equity securities with some additional funding from other traditional financing sources, including term notes, until such time that funds provided by operations are sufficient to fund working capital requirements. The financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.
Fair Value of Financial Instruments	Fair Value of Financial Instruments As of September 30, 2019, the Company had the following assets and liabilities measured at fair value on a recurring basis. Total Level 1 Level 2 Level 3 Derivative Liability $ 1,358,964 $ - $ - $ 1,358,964 Total Liabilities measured at fair value $ 1,358,964 $ - $ - $ 1,358,964 As of December 31, 2018, the Company had the following assets and liabilities measured at fair value on a recurring basis. Total Level 1 Level 2 Level 3 Derivative Liability $ 1,584,102 $ - $ - $ 1,584,102 Total Liabilities measured at fair value $ 1,584,102 $ - $ - $ 1,584,102

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
Summary of Assets and Liabilities Fair Value on Recurring Basis	As of September 30, 2019, the Company had the following assets and liabilities measured at fair value on a recurring basis. Total Level 1 Level 2 Level 3 Derivative Liability $ 1,358,964 $ - $ - $ 1,358,964 Total Liabilities measured at fair value $ 1,358,964 $ - $ - $ 1,358,964 As of December 31, 2018, the Company had the following assets and liabilities measured at fair value on a recurring basis. Total Level 1 Level 2 Level 3 Derivative Liability $ 1,584,102 $ - $ - $ 1,584,102 Total Liabilities measured at fair value $ 1,584,102 $ - $ - $ 1,584,102

Equity Transactions (Tables)

Equity Transactions (Tables)	9 Months Ended
	Sep. 30, 2019
Equity [Abstract]
Summary of Stock Options Activity	The following is a summary of the status of all Company’s stock options as of September 30, 2019 and changes during the nine months ended on that date: Weighted Number Average Remaining Intrinsic Options Price Life (yrs) Value Outstanding at December 31, 2018 2,850,000 $ 0.80 2.2 $ - Granted - - Exercised - - Cancelled - - Outstanding at September 30, 2019 2,850,000 0.80 1.4 $ - Options exercisable at September 30, 2019 2,850,000 $ 0.80 1.4 $ -
Schedule of Warrant Activity	The following is a summary of the status of the Company’s warrants as of September 30, 2019 and changes during the nine months ended on that date: Weighted Number of Average Remaining Intrinsic Warrants Price Life (yrs.) Value Outstanding at December 31, 2018 3,778,179 $ 0.48 1.4 $ - Granted - - - - Exercised - - - - Cancelled 477,429 - - - Outstanding at September 30, 2019 3,300,750 $ 0.52 1.1 $ 22.240 Warrants exercisable at September 30, 2019 3,300,750 $ 0.52 1.1 $ 22,240

Derivative Valuation (Tables)

Derivative Valuation (Tables)	9 Months Ended
	Sep. 30, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Derivative Liability	During the nine months ended September 30, 2019, the Company had the following activity in the derivative liability account: Notes Warrants Total Derivative liability at December 31, 2018 $ 1,402,721 $ 181,381 $ 1,584,102 Addition of new conversion option derivatives 3,631,177 - 3,631,177 Conversion of note derivatives (1,107,498 ) - (1,107,498 ) Change in fair value (2,582,681 ) (166,137 ) (2,748,818 ) Derivative liability at September 30, 2019 $ 1,343,719 $ 15,244 $ 1,358,963
Schedule of Assumptions Used Black Scholes Valuation of Derivative	The significant assumptions used in the Black Scholes valuation of the derivative are as follows: Stock price at valuation date $ .03-.10 Exercise price of warrants $ .25 Conversion rate of convertible debt $ .445 Risk free interest rate 1.6%-2.42 % Stock volatility factor 102.5%-190 % Years to Maturity .06 – 2.72 Expected dividend yield None

The Company (Details Narrative)

The Company (Details Narrative) $ in Thousands	9 Months Ended
	Sep. 30, 2019USD ($)
Physical therapy investment, description	PHZIO is the first real-time remote monitored 1-to-many MSK physical therapy platforms for home use
Physical Therapy Market [Member]
Physical therapy assesment and exercise platform	$ 30,000,000
MSK [Member]
Physical therapy assesment and exercise platform	4,000,000
Wellness Industry [Member]
Physical therapy assesment and exercise platform	$ 8,000,000

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Accounting Policies [Abstract]
Revenues
Accumulated loss	$ (26,025,365)	$ (21,401,234)

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Summary of Assets and Liabilities Fair Value on Recurring Basis (Details) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Derivative Liability	$ 1,358,964	$ 1,584,102
Total Liabilities measured at fair value	1,358,964	1,584,102
Level 1 [Member]
Derivative Liability
Total Liabilities measured at fair value
Level 2 [Member]
Derivative Liability
Total Liabilities measured at fair value
Level 3 [Member]
Derivative Liability	1,358,964	1,584,102
Total Liabilities measured at fair value	$ 1,358,964	$ 1,584,102

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	Apr. 02, 2017	Nov. 30, 2016	Sep. 30, 2019	Dec. 31, 2018
Accrued directors' fees			$ 153,250	$ 211,000
Accrued executive compensation			776,464	1,113,470
Officers and Directors [Member]
Due to related party			44,991	$ 3,076
Programming Company [Member]
Monthly base fee		$ 100,000
Fee payable per month		$ 50,000
Related party transaction, description of transaction		The agreement is for additional features to be programmed for the launch of the PHZIO platform. The Company is to pay a monthly base fee of $100,000 for the development and compensation for the Company's CEO and CTO. Following payment of the initial $100,000, the Company is obligated to only pay $50,000 monthly until the PC has successfully signed and collected the first monthly service fee for 100 physical therapy clinics to use the PHZIO platform.
Amount indebted		$ 225,000
Shares issued for services, shares	25,280,899
Shares issued price per share	$ 0.0089
Percentage of patient insurance reimbursements received		40.00%
Due to related party			$ 627,832

Convertible Notes Payable (Deta

Convertible Notes Payable (Details Narrative)

Sep. 19, 2019USD ($)Integer

Sep. 17, 2019USD ($)$ / sharesshares

Sep. 09, 2019USD ($)Integershares

Sep. 04, 2019USD ($)Integer

Jul. 30, 2019USD ($)Integer

Jul. 19, 2019USD ($)

Jul. 12, 2019USD ($)shares

Jul. 11, 2019USD ($)Integer

Jul. 09, 2019USD ($)Integer

Jul. 08, 2019USD ($)Integer

Jul. 05, 2019Integer

Jul. 02, 2019USD ($)Integer

May 28, 2019USD ($)

May 13, 2019USD ($)Integer

May 06, 2019USD ($)

Apr. 02, 2019USD ($)Integer

Mar. 25, 2019USD ($)

Mar. 21, 2019USD ($)Integershares

Mar. 18, 2019USD ($)Integer

Feb. 22, 2019USD ($)

Jan. 29, 2019USD ($)

Jan. 29, 2019USD ($)Integer

Jan. 09, 2019USD ($)Integer

Jan. 08, 2019USD ($)Integer

Sep. 30, 2018USD ($)

Mar. 18, 2018Integer

Nov. 30, 2018USD ($)Integer

Oct. 31, 2018USD ($)Integer

Sep. 30, 2018USD ($)

Aug. 31, 2018USD ($)Integer$ / shares

Jul. 31, 2018USD ($)Integer$ / sharesshares

Sep. 30, 2019USD ($)$ / shares

Jun. 30, 2019USD ($)

Mar. 31, 2019USD ($)

Sep. 30, 2018USD ($)

Jun. 30, 2018USD ($)

Mar. 31, 2018USD ($)

Sep. 30, 2019USD ($)$ / sharesshares

Sep. 30, 2018USD ($)

Dec. 31, 2018USD ($)$ / sharesshares

Oct. 31, 2019USD ($)Integer

Sep. 12, 2019USD ($)

Jul. 10, 2019USD ($)

May 31, 2018USD ($)

Feb. 28, 2018USD ($)

Jan. 31, 2018USD ($)

Debt instrument conversion of debt, value

$ 531,425

$ 53,755

$ 347,487

$ 620,490

$ 636,706

$ 213,292

Third Tranche [Member]

Proceeds from debt

$ 60,000

Accrued interest

$ 1,350

$ 1,350

Prepayment penalty

$ 30,000

12% Convertible Promissory Note Seven [Member]

Interest expense

3,379

First Tranche at Signing Date [Member]

Debt face amount

$ 60,000

First Extension Agreement [Member] | Note Holder [Member]

Convertible notes, description

The Company executed a convertible note conversion period extension agreement on a note dated October 28, 2018, within which the period of conversion by note holder was extended to May 27, 2019

Payment to note holder

$ 16,031

Second Extension Agreement [Member] | Note Holder [Member]

Convertible notes, description

The Company executed a second extension agreement on this note within which the period of conversion by note holder was extended to June 11, 2019. The Company paid $16,105 to note holder for this extension agreement.

Debt instrument conversion of debt, value

308,000

Interest expense

$ 16,337

Debt instrument conversion of debt, shares | shares

8,987,253

Payment to note holder

$ 16,105

Second Extension Agreement [Member] | Note Holder [Member] | Minimum [Member]

Conversion price per share | $ / shares

$ .035

$ .035

Second Extension Agreement [Member] | Note Holder [Member] | Maximum [Member]

Conversion price per share | $ / shares

$ .04508

$ .04508

Extension Agreement [Member]

Notes Payable

$ 21,560

$ 22,410

8% Convertible Promissory Note One [Member]

Accrued interest

$ 17,547

$ 17,547

$ 4,489

Debt face amount

$ 308,000

$ 278,000

278,000

$ 110,000

Debt maturity date

Jan. 8, 2020

Oct. 12, 2018

Original issue discount

$ 28,000

Transaction costs

$ 10,000

Convertible debt percentage

70.00%

Number of trading days | Integer

20

Convertible notes, description

The convertible note converts into common stock of the Company at a conversion price that shall be equal to the 70% of the average of the two lowest per share trading prices for the twenty (20) trading days prior to the conversion date

Debt instrument conversion of debt, value

30,000

Interest expense

$ 1,687

Debt instrument conversion of debt, shares | shares

905,333

2,412,827

Conversion price per share | $ / shares

$ 0.035

$ 0.035

$ 0.04745

8% Convertible Promissory Note Two [Member]

Accrued interest

$ 17,029

$ 17,029

$ 5,928

Debt face amount

$ 146,000

77,000

146,000

Debt maturity date

Jan. 8, 2020

Dec. 5, 2018

Original issue discount

$ 28,000

$ 80,500

Transaction costs

$ 10,000

Convertible debt percentage

70.00%

Number of trading days | Integer

20

Convertible notes, description

The convertible note converts into common stock of the Company at a conversion price that shall be equal to the 70% of the average of the two lowest per share trading prices for the twenty (20) trading days prior to the conversion date

Debt instrument conversion of debt, value

$ 162,000

Debt instrument conversion of debt, shares | shares

4,424,400

2,402,436

Conversion price per share | $ / shares

$ 0.036

8% Convertible Promissory Note Two [Member] | Minimum [Member]

Conversion price per share | $ / shares

$ .035

$ .035

Debt interest stated rate

10.00%

10.00%

10.00%

10.00%

8% Convertible Promissory Note Two [Member] | Maximum [Member]

Conversion price per share | $ / shares

$ .042

$ .042

Debt interest stated rate

15.00%

15.00%

15.00%

15.00%

12% Convertible Promissory Note One [Member]

Prepayment penalty

42,010

Debt face amount

$ 114,000

$ 91,300

Debt maturity date

Oct. 30, 2019

Oct. 30, 2018

Original issue discount

$ 11,000

Transaction costs

$ 3,000

Convertible debt percentage

70.00%

Number of trading days | Integer

10

Convertible notes, description

The convertible note converts into common stock of the Company at a conversion price that shall be equal to the 70% average of the two lowest per share trading prices for the ten (10) trading days prior to the conversion date

Interest expense

$ 6,028

Debt instrument conversion of debt, shares | shares

1,630,799

12% Convertible Promissory Note One [Member] | Minimum [Member]

Accrued interest

$ 4,980

Conversion price per share | $ / shares

$ 0.0583

12% Convertible Promissory Note One [Member] | Maximum [Member]

Conversion price per share | $ / shares

$ 0.0603

12% Convertible Promissory Note Two [Member]

Prepayment penalty

21,369

Debt face amount

$ 58,300

$ 58,300

$ 63,800

Debt maturity date

Nov. 15, 2019

Nov. 30, 2018

Original issue discount

$ 5,300

Transaction costs

$ 3,000

Convertible debt percentage

70.00%

Number of trading days | Integer

10

Convertible notes, description

The convertible note converts into common stock of the Company at a conversion price that shall be equal to the 70% average of the two lowest per share trading prices for the ten (10) trading days prior to the conversion date

Interest expense

2,753

Debt instrument conversion of debt, shares | shares

1,309,799

12% Convertible Promissory Note Two [Member] | Minimum [Member]

Accrued interest

$ 3,480

Conversion price per share | $ / shares

$ 0.0487

12% Convertible Promissory Note Two [Member] | Maximum [Member]

Conversion price per share | $ / shares

$ 0.0532

At Signing [Member] | Securities Purchase Agreement [Member]

Debt face amount

$ 65,000

Forty-Five (45) Days After Signing Date [Member] | Securities Purchase Agreement [Member]

Debt face amount

100,000

Forty-Five (45) Days After the Second Closing Date [Member] | Securities Purchase Agreement [Member]

Debt face amount

200,000

12% Fixed Convertible Promissory Note One [Member]

Prepayment penalty

$ 19,500

12% Convertible Promissory Note Three [Member]

Accrued interest

$ 3,780

Prepayment penalty

$ 16,555

Debt face amount

$ 47,300

$ 72,450

Debt maturity date

Jan. 30, 2020

Dec. 30, 2018

Original issue discount

$ 4,300

Transaction costs

$ 3,000

Convertible debt percentage

70.00%

Number of trading days | Integer

10

Convertible notes, description

The convertible note converts into common stock of the Company at a conversion price equal to 70% of the average of the lowest two (2) trading prices during the ten (10) trading day period ending on the last complete trading day prior to the conversion date

Interest expense

3,226

Debt instrument conversion of debt, shares | shares

1,877,796

12% Convertible Promissory Note Three [Member] | Minimum [Member]

Conversion price per share | $ / shares

$ .0393

12% Convertible Promissory Note Three [Member] | Maximum [Member]

Conversion price per share | $ / shares

$ .0437

3% Convertible Promissory Note [Member]

Accrued interest

$ 2,925

2,925

Debt face amount

360,000

Original issue discount

$ 60,000

Convertible debt percentage

65.00%

Number of trading days | Integer

25

Convertible notes, description

The convertible note converts into common stock of the Company at a conversion price that shall be equal to 65% of the lesser of (i) lowest trading price or (ii) the lowest closing bid price on the OTCQB during the twenty-five (25) trading day period ending on the last complete trading day prior to the conversion date

Debt instrument, term

12 months

12% Fixed Convertible Promissory Note [Member]

Debt face amount

$ 1,500,000

12% Convertible Promissory Note Four [Member]

Accrued interest

$ 2,700

Debt face amount

$ 51,750

Debt maturity date

Mar. 1, 2019

Convertible debt percentage

75.00%

Number of trading days | Integer

30

Convertible notes, description

The convertible note converts into common stock of the Company at a conversion price that shall be equal to 65% of the lowest trading price during the thirty (30) day trading period ending on the last complete trading day prior to the conversion date

Interest expense

57,337

Debt instrument conversion of debt, shares | shares

658,722

Number of restrick stock issued | shares

3,260,870

12% Convertible Promissory Note Four [Member] | Minimum [Member]

Conversion price per share | $ / shares

$ .081

12% Convertible Promissory Note Four [Member] | Maximum [Member]

Conversion price per share | $ / shares

$ .085

12% Convertible Promissory Note Four [Member] | Commitment Fee [Member]

Number of restrick stock issued | shares

1,000,000

12% Convertible Promissory Note Five [Member]

Prepayment penalty

20,405

20,405

Debt face amount

$ 58,300

$ 56,500

Debt maturity date

Feb. 15, 2020

Apr. 17, 2019

Original issue discount

$ 5,300

$ 6,500

Transaction costs

$ 3,000

Convertible debt percentage

70.00%

75.00%

Number of trading days | Integer

10

30

Convertible notes, description

The convertible note converts into common stock of the Company at a conversion price equal to 70% of the average of the lowest two (2) trading prices during the ten (10) trading day period ending on the last complete trading day prior to the conversion date

The convertible notes convert into common stock of the Company at conversion price that shall be equal to the lesser of: (i) $0.21 or (ii) 75% of the lowest per share trading price for the thirty (30) trading days before the issued date of this note.

Debt instrument conversion of debt, value

$ 8,000

Interest expense

3,811

$ 2,991

Debt instrument conversion of debt, shares | shares

100,000

Conversion price per share | $ / shares

$ 0.21

12% Convertible Promissory Note Six [Member]

Debt face amount

$ 110,000

$ 28,250

Debt maturity date

Feb. 13, 2020

Apr. 17, 2019

Original issue discount

$ 10,000

$ 3,250

Transaction costs

$ 3,000

Convertible debt percentage

65.00%

75.00%

Number of trading days | Integer

20

30

Convertible notes, description

The convertible note converts into common stock of the Company at conversion price that shall be equal to the 65% of the lowest closing price for the twenty (20) trading days prior to the conversion date.

The convertible notes convert into common stock of the Company at conversion price that shall be equal to the lesser of: (i) $0.21 or (ii) 75% of the lowest per share trading price for the thirty (30) trading days before the issued date of this note.

Debt instrument conversion of debt, value

$ 4,000

Interest expense

5,063

$ 1,495

Debt instrument conversion of debt, shares | shares

50,000

Conversion price per share | $ / shares

$ 0.21

Two Back-End Notes [Member]

Original issue discount

$ 16,500

Convertible debt percentage

70.00%

Number of trading days | Integer

20

Convertible notes, description

The convertible notes convert into common stock of the Company at conversion price that shall be equal to the 70% of the average of the two (2) lowest per share trading prices for the prior twenty (20) trading days including the conversion date

Interest expense

3,038

Investment

$ 154,000

Convertible Note [Member] | Minimum [Member]

Convertible debt percentage

65.00%

Number of trading days | Integer

30

Convertible notes, description

The conversion price from 75% to 65% of the lowest trading price during the thirty (30) trading days prior to the conversion date

12% Convertible Promissory Note Seven [Member]

Debt face amount

$ 140,800

$ 77,000

Debt maturity date

Apr. 5, 2019

Original issue discount

$ 7,000

Convertible debt percentage

75.00%

Number of trading days | Integer

10

Convertible notes, description

The convertible notes convert into common stock of the Company at conversion price that shall be equal to the lesser of: (i) $0.06 or (ii) 75% of the lowest per share trading price for the ten (10) trading days before the conversion date.

Interest expense

4,870

Conversion price per share | $ / shares

$ 0.06

12% Convertible Promissory Note Seven [Member] | Minimum [Member]

Debt interest stated rate

10.00%

10.00%

10.00%

10.00%

12% Convertible Promissory Note Seven [Member] | Maximum [Member]

Debt face amount

$ 80,500

$ 80,500

$ 80,500

$ 80,500

Debt interest stated rate

15.00%

15.00%

15.00%

15.00%

12% Convertible Promissory Note Seven [Member]

Debt maturity date

Apr. 30, 2020

Original issue discount

$ 12,800

Transaction costs

$ 3,000

Convertible debt percentage

70.00%

Number of trading days | Integer

10

Convertible notes, description

The convertible note converts into common stock of the Company at a conversion price equal to 70% of the average of the lowest two (2) trading prices during the ten (10) trading day period ending on the last complete trading day prior to the conversion date.

12% Convertible Promissory Note Eight [Member]

Debt face amount

$ 113,000

$ 60,950

Debt maturity date

Jul. 9, 2020

Apr. 30, 2019

Original issue discount

$ 10,000

$ 7,950

Transaction costs

$ 3,000

Convertible debt percentage

65.00%

75.00%

Number of trading days | Integer

20

10

Convertible notes, description

The convertible note converts into common stock of the Company at a conversion price that shall be equal to the 65% average of the lowest per share trading prices for the twenty (20) trading days prior to the conversion date

The convertible notes convert into common stock of the Company at conversion price that shall be equal to the lesser of: (i) $.20 or (ii) variable conversion price which is 75% of the average of the lowest (2) VWAP for the ten (10) trading day period ending on the latest compete trading day prior to the conversion date.

Interest expense

2,712

3,647

Conversion price per share | $ / shares

$ 0.20

8% Fixed Convertible Promissory Note Four [Member]

Debt face amount

$ 235,000

Debt maturity date

Jul. 11, 2020

Original issue discount

$ 25,200

Transaction costs

$ 10,000

Convertible debt percentage

65.00%

Number of trading days | Integer

20

Convertible notes, description

The convertible note converts into common stock of the Company at a conversion price that shall be equal to the 65% average of the lowest per share trading prices for the prior twenty (20) trading days including the conversion date.

Interest expense

3,605

12% Convertible Promissory Note Nine [Member]

Debt face amount

$ 250,000

$ 58,300

Debt maturity date

Apr. 19, 2020

Jun. 15, 2019

Original issue discount

$ 37,500

$ 5,300

Transaction costs

$ 5,000

Convertible debt percentage

65.00%

75.00%

Number of trading days | Integer

25

10

Convertible notes, description

The convertible note converts into common stock of the Company at a conversion price that shall be equal to 65% of the average of the lowest per share trading prices for the twenty-five (25) trading days prior to the conversion date.

The convertible notes convert into common stock of the Company at conversion price that shall be equal to the lesser of: (i) $.20 or (ii) variable conversion price which is 75% of the average of the two (2) lowest VWAP for the ten (10) trading day period ending on the latest compete trading day prior to the conversion date.

Debt instrument conversion of debt, value

5,425

Interest expense

2,338

Conversion price per share | $ / shares

$ 0.20

12% Convertible Promissory Note Ten [Member]

Debt face amount

$ 38,500

$ 47,300

Debt maturity date

Apr. 30, 2020

Jul. 15, 2019

Original issue discount

$ 3,500

$ 7,300

Transaction costs

$ 1,500

Convertible debt percentage

65.00%

70.00%

Number of trading days | Integer

20

10

Convertible notes, description

The convertible notes convert into common stock of the Company at a conversion price that shall be equal to the 65% of the lowest per share trading prices for the twenty (20) trading days prior to the conversion date.

The convertible notes convert into common stock of the Company at conversion price that shall be equal to the variable conversion price which is 70% of the average of the two (2) lowest VWAP for the ten(10) trading day period ending on the latest compete trading day prior to the conversion date.

Debt instrument conversion of debt, value

1,380

Interest expense

1,291

12% Convertible Promissory Note Eleven [Member]

Debt face amount

$ 58,300

Debt maturity date

Jul. 15, 2020

Original issue discount

$ 5,300

Transaction costs

$ 3,000

Convertible debt percentage

70.00%

Number of trading days | Integer

10

Convertible notes, description

The convertible note converts into common stock of the Company at a conversion price equal to 70% of the average of the lowest two (2) trading prices during the ten (10) trading day period ending on the last complete trading day prior to the conversion date

Debt instrument conversion of debt, value

364

12% Convertible Promissory Note Twelve [Member]

Debt face amount

$ 154,000

Debt maturity date

Jan. 9, 2020

Original issue discount

$ 14,000

Transaction costs

$ 5,000

Convertible debt percentage

70.00%

Number of trading days | Integer

20

Convertible notes, description

The convertible note converts into common stock of the Company at conversion price that shall be equal to the 70% of the average of the two (2) lowest per share trading prices for the twenty (20) trading days prior to the conversion date

Debt instrument conversion of debt, value

641

12% Convertible Promissory Note Thirteen [Member]

Debt face amount

$ 154,000

Debt maturity date

Jan. 8, 2020

Original issue discount

$ 14,000

Transaction costs

$ 5,000

Convertible debt percentage

70.00%

Number of trading days | Integer

20

Convertible notes, description

The convertible notes convert into common stock of the Company at conversion price that shall be equal to the 70% of the average of the two (2) lowest per share trading prices for the prior twenty (20) trading days including the conversion date

Debt instrument conversion of debt, value

371

8% Convertible Promissory Note Three [Member]

Accrued interest

$ 415

Debt face amount

$ 125,000

Debt maturity date

May 10, 2019

Debt instrument conversion of debt, shares | shares

1,626,268

Accrued interest not yet converted

$ 5,288

8% Convertible Promissory Note Three [Member] | Minimum [Member]

Conversion price per share | $ / shares

$ 0.0628

8% Convertible Promissory Note Three [Member] | Maximum [Member]

Conversion price per share | $ / shares

$ 0.1032

8% Convertible Promissory Note Four [Member]

Debt face amount

$ 165,000

Debt maturity date

Oct. 12, 2019

Original issue discount

$ 15,000

Convertible debt percentage

65.00%

Number of trading days | Integer

15

Convertible notes, description

The convertible notes convert into common stock of the Company at conversion price that shall be equal to 65% of the lowest per share closing price during the fifteen (15) trading days immediately preceding the date of the notice of conversion.

Interest expense

$ 2,594

8% Convertible Promissory Note Five [Member]

Debt face amount

$ 308,000

Debt maturity date

Oct. 29, 2019

Original issue discount

$ 33,000

Convertible debt percentage

70.00%

Number of trading days | Integer

20

Convertible notes, description

The convertible notes convert into common stock of the Company at conversion price that shall be equal to the 70% of the average of the two (2) lowest per share trading prices for the twenty (20) trading days prior to the conversion date.

Interest expense

4,118

8% Convertible Promissory Note Six [Member]

Debt face amount

$ 308,000

Debt maturity date

Oct. 29, 2019

Original issue discount

$ 33,000

Convertible debt percentage

70.00%

Number of trading days | Integer

20

Convertible notes, description

The convertible notes convert into common stock of the Company at conversion price that shall be equal to the 70% of the average of the two (2) lowest per share trading prices for the twenty (20) trading days prior to the conversion date.

Interest expense

4,118

8% Convertible Promissory Note Seven [Member]

Debt face amount

$ 125,000

Debt maturity date

May 10, 2019

Original issue discount

$ 10,000

Convertible debt percentage

72.00%

Number of trading days | Integer

10

Convertible notes, description

The convertible notes convert into common stock of the Company at conversion price that shall be equal to 72% of the lowest VWAP for the ten (10) trading days prior to and including the conversion date.

Interest expense

1,123

Fourth Tranche [Member]

Proceeds from debt

$ 30,000

Accrued interest

534

534

Debt face amount

20,300

20,300

Fourth Tranche [Member] | Convertible Debt Holder [Member]

Debt instrument conversion of debt, value

$ 9,700

Debt instrument conversion of debt, shares | shares

340,000

Conversion price per share | $ / shares

$ .03

Six Tranches [Member]

Debt face amount

$ 365,000

Debt maturity date

Mar. 18, 2022

Convertible debt percentage

70.00%

Number of trading days | Integer

10

Convertible notes, description

The debentures convert into common stock of the Company at a conversion price equal to the lesser of (i) $.12 or (ii) seventy percent (70%) of the lowest traded price (as reported by Bloomberg LP) of the common stock for the ten (10) trading days prior to the conversion date

Debt instrument, original issue discount

10.00%

Debt instrument, commitment fee

$ 5,000

Six Tranches [Member] | 3% Convertible Promissory Note [Member]

Debt face amount

$ 180,000

Original issue discount

$ 10,000

Convertible debt percentage

75.00%

Number of trading days | Integer

20

Convertible notes, description

The convertible notes convert into common stock of the Company at conversion price that shall be equal to 75% of the market price which is lowest trading price during the twenty (20) trading day period ending on the last complete trading day prior to the conversion date.

Debt instrument, term

12 months

First Tranche [Member] | 12% Convertible Promissory Note Two [Member]

Proceeds from debt

$ 65,000

First Tranche [Member] | 3% Convertible Promissory Note [Member]

Prepayment penalty

30,000

30,000

First Tranche [Member] | 12% Convertible Promissory Note Four [Member]

Proceeds from debt

$ 750,000

Debt instrument, original issue discount

10.00%

Debt instrument, term

6 months

First Tranche [Member] | 3% Convertible Promissory Note [Member]

Proceeds from debt

$ 60,000

First Tranche [Member] | 8% Convertible Promissory Note Four [Member]

Proceeds from debt

110,000

Second Tranche [Member] | 3% Convertible Promissory Note [Member]

Proceeds from debt

$ 37,500

Debt face amount

$ 37,500

$ 37,500

Second Tranche [Member] | 12% Convertible Promissory Note Four [Member]

Proceeds from debt

$ 350,000

Debt maturity date

Jan. 20, 2020

Debt instrument, original issue discount

10.00%

Debt instrument, term

6 months

Number of restrick stock issued | shares

2,692,307

Second Tranche [Member] | 3% Convertible Promissory Note [Member]

Proceeds from debt

$ 30,000

Second Tranche [Member] | 8% Convertible Promissory Note Four [Member]

Proceeds from debt

$ 55,000

Third Tranche [Member] | 12% Convertible Promissory Note Four [Member]

Debt maturity date

Mar. 12, 2020

Number of restrick stock issued | shares

4,000,000

Three Tranches [Member] | 3% Convertible Promissory Note [Member]

Interest expense

$ 1,102

Equity Transactions (Details Na

Equity Transactions (Details Narrative) - USD ($)	Sep. 25, 2019	Jul. 10, 2019	May 17, 2019	Apr. 02, 2019	Mar. 22, 2019	Feb. 07, 2019	Nov. 01, 2018	Jan. 02, 2018	Nov. 14, 2019	Jul. 31, 2018	Jun. 30, 2018	Jan. 31, 2018	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Sep. 30, 2019	Sep. 30, 2018	Oct. 10, 2019	Jul. 09, 2019	Dec. 31, 2018	Apr. 09, 2015
Preferred stock, shares authorized													20,000,000						20,000,000				20,000,000
Preferred stock, par value													$ 0.001						$ 0.001				$ 0.001
Deferred compensation													$ 3,000,000						$ 3,000,000
Stock option expense																				$ 359,245
Common stock, shares authorized													1,900,000,000						1,900,000,000				1,900,000,000
Shares issued during period for consulting services, value													$ 152,572	$ 158,084	$ 181,549	$ 78,865	$ 112,100	$ 138,600
Shares issued during period, value														59,100
Shares issued for debt conversion, value													$ 531,425	$ 53,755	$ 347,487	620,490	$ 636,706	$ 213,292
Common stock, par value													$ 0.001						$ 0.001				$ 0.001
Stock option plan expense																			$ 0	$ 217,188
United States Federal District Count [Member]
Shares issued for debt conversion, shares																				4,000,000
Shares issued for debt conversion, value																				$ 236,868
Accrued interest																56,817				$ 56,817
Promissory Note [Member] | Second Tranche [Member]
Shares issued during period, shares		2,692,307
Shares issued during period, value		$ 167,462
Promissory Note [Member] | Third Tranche [Member]
Shares issued during period, shares																			4,000,000
Shares issued during period, value																			$ 280,000
Consulting Service [Member]
Shares issued during period, shares	250,000
Shares issued during period, value	$ 13,750
Convertible Notes [Member]
Shares issued for debt conversion, shares																			20,270,431	26,598,252
Shares issued for debt conversion, value																			$ 932,667	$ 1,190,189
Principal amount													$ 889,950						889,950
Accrued interest													40,217			$ 163,157			40,217	$ 163,157
Diligence fee													$ 2,500						$ 2,500
Shares issued for financing fees for convertible debt, shares																			1,590,331
Shares issued for financing fees for convertible debt, value																			$ 72,000
Consulting Services [Member]
Shares issued during period for consulting services, shares			500,000			250,000							500,000
Shares issued during period for consulting services, value			$ 53,000			$ 30,500							$ 31,200
Equity Purchase Agreement [Member]
Stock issued for period capital call notice				800,000
Stock issued for period capital call notice, value				$ 59,100
Consulting Agreement [Member]
Shares issued during period for consulting services, shares										1,500,000	125,000
Marketing and Consulting Services [Member]
Shares issued during period for consulting services, shares																				3,875,000
Shares issued during period for consulting services, value																				$ 329,565
Subsequent Event [Member]
Common stock, shares authorized																					1,900,000,000
Subsequent Event [Member] | Convertible Notes [Member]
Shares issued for debt conversion, shares									45,502,112
Shares issued for debt conversion, value									$ 508,655
Principal amount									436,906
Accrued interest									$ 69,199
Subsequent Event [Member] | Consulting Agreement [Member]
Shares issued during period for consulting services, shares									374,999
Shares issued during period for consulting services, value									$ 12,150
Preferred Shares [Member]
Conversion of stock, shares																			40
Conversion of stock, description																			The shares are eligible for conversion after 24 months into 40 shares of common stock per each preferred share. The value of the issued shares was calculated on the basis of 40 shares per preferred share at the common share value on the date of issuance.
Vested preferred shares																			125,000
Stock option expense																			$ 255,000
Accrued directors fees																			33,750
Expenses																			86,250
Total expenses																			$ 375,000
Shares issued during period for consulting services, shares
Shares issued during period for consulting services, value
Shares issued during period, shares
Shares issued during period, value
Shares issued for debt conversion, shares
Shares issued for debt conversion, value
Common Stock [Member]
Common stock, shares authorized													900,000,000						900,000,000			400,000,000
Shares issued during period for consulting services, shares													2,274,997	1,650,435	1,324,560	1,325,000	1,200,000	1,350,000
Shares issued during period for consulting services, value													$ 2,275	$ 1,650	$ 1,325	$ 1,325	$ 1,200	$ 1,350
Shares issued during period, shares														800,000
Shares issued during period, value														$ 800
Shares issued for debt conversion, shares													13,991,743	1,181,433	5,097,255	12,943,900	13,708,947	3,945,407
Shares issued for debt conversion, value													$ 13,992	$ 1,181	$ 5,098	$ 12,944	$ 13,710	$ 3,945
Common Stock [Member] | Consulting Agreement [Member]
Shares issued during period for consulting services, shares											1,500,000
Shares issued during period for consulting services, value											$ 105,000
Common Stock [Member] | Subsequent Event [Member]
Shares issued during period for consulting services, shares									1,050,000
Shares issued during period for consulting services, value									$ 39,750
Officers, Directors and Consultants [Member]
Preferred stock, shares authorized													1,000,000						1,000,000
Officers, Directors and Consultants [Member] | 2018 Equity Incentive Plan [Member]
Number of common stock for sale plan							17,400,000
Institutional Investor [Member]
Common stock, par value											$ 0.001						$ 0.001
Institutional Investor [Member] | Maximum [Member]
Shares issued during period, shares											1,500,000
Institutional Investor [Member] | Promissory Note [Member]
Shares issued during period, shares					3,260,870
Shares issued during period, value					$ 375,000
Shares issued for commiitment fee, shares					1,000,000
Shares issued for commiitment fee, value					115,000
Institutional Investor [Member] | Equity Purchase Agreement [Member]
Stock issued during period restricted stock											1,000,000
Stock issued during period restricted stock, value											$ 70,000
Consultants [Member] | Consulting Agreement [Member]
Shares issued during period for consulting services, shares																			4,749,992
Shares issued during period for consulting services, value																			$ 466,403
Board of Directors [Member] | 2018 Equity Incentive Plan [Member]
Number of common stock placed								20,000,000
Board of Directors [Member] | Advisory Agreement [Member]
Shares issued as compensation, shares												800,000
Shares issued as compensation, value												$ 104,000
Board of Directors [Member] | Warrants [Member]
Unexercised warrants granted																								417,429

Equity Transactions - Summary o

Equity Transactions - Summary of Stock Options Activity (Details)	9 Months Ended
	Sep. 30, 2019USD ($)$ / sharesshares
Equity [Abstract]
Number of Stock Options Outstanding, Beginning Balance | shares	2,850,000
Number of Stock Options Outstanding, Granted | shares
Number of Stock Options Outstanding, Exercised | shares
Number of Stock Options Outstanding, Cancelled | shares
Number of Stock Options Outstanding, Ending Balance | shares	2,850,000
Number of Stock Options Exercisable, Ending Balance | shares	2,850,000
Weighted Average Exercise Price Outstanding, Beginning Balance | $ / shares	$ 0.80
Weighted Average Exercise Price, Granted | $ / shares
Weighted Average Exercise Price, Exercised | $ / shares
Weighted Average Exercise Price, Cancelled | $ / shares
Weighted Average Exercise Price Outstanding, Ending Balance | $ / shares	0.80
Weighted Average Exercise Price Options Exercisable, Ending Balance | $ / shares	$ 0.80
Remaining Life (yrs) Outstanding, Beginning Balance	2 years 2 months 12 days
Remaining Life (yrs) Outstanding, Ending Balance	1 year 4 months 24 days
Remaining Life (yrs) Options Exercisable, Ending Balance	1 year 4 months 24 days
Intrinsic Value Outstanding, Beginning Balance | $
Intrinsic Value Outstanding, Ending Balance | $
Intrinsic Value Options Exercisable, Ending Balance | $

Equity Transactions - Schedule

Equity Transactions - Schedule of Warrant Activity (Details) - Warrants [Member]	9 Months Ended
	Sep. 30, 2019$ / sharesshares
Number of Warrants Outstanding, Beginning Balance | shares	3,778,179
Number of Warrants Granted | shares
Number of Warrants Exercised | shares
Number of Warrants Cancelled | shares	477,429
Number of Warrants Outstanding, Ending Balance | shares	3,300,750
Number of Warrants exercisable, Ending balance | shares	3,300,750
Weighted Average Exercise Price, Warrants Outstanding, Beginning Balance	$ 0.48
Weighted Average Exercise Price, Warrants Granted
Weighted Average Exercise Price, Warrants Exercised
Weighted Average Exercise Price, Warrants Cancelled
Weighted Average Exercise Price, Warrants Outstanding, Ending Balance	0.52
Weighted Average Exercise Price Exercisable, Ending	$ 0.52
Remaining Life (yrs.) Outstanding, Beginning	1 year 4 months 24 days
Remaining Life (yrs.) Outstanding, Ending	1 year 1 month 6 days
Remaining Life (yrs.) Exercisable, Ending	1 year 1 month 6 days
Intrinsic Value Outstanding, Beginning Balance
Intrinsic Value, Ending Balance	22.240
Intrinsic Value Exercisable, Ending Balance	$ 22.240

Commitments, Contingencies (Det

Commitments, Contingencies (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Percentage of returned funds	90.00%
Percentage of funds proceed	10.00%
Percentage of required funds	90.00%
Escrowed funds	$ 100,000
Proceeds from escrowed funds	10,000
Return of escrowed funds	90,000
Contingent liability	$ 90,000	$ 90,000
Escrow Trust [Member]
Percentage of subscription proceeds	10.00%
Trust account balance	$ 90,000

Derivative Valuation (Details N

Derivative Valuation (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Amortized of debt discount	$ 2,690,435	$ 284,392

Derivative Valuation - Schedule

Derivative Valuation - Schedule of Derivative Liability (Details)	9 Months Ended
	Sep. 30, 2019USD ($)
Derivative liability, beginning balance	$ 1,584,102
Addition of new conversion option derivatives	3,631,177
Conversion of note derivatives	(1,107,498)
Changes in fair value	(2,748,818)
Derivative liability, ending balance	1,358,963
Notes [Member]
Derivative liability, beginning balance	1,402,721
Addition of new conversion option derivatives	3,631,177
Conversion of note derivatives	(1,107,498)
Changes in fair value	(2,582,681)
Derivative liability, ending balance	1,343,719
Warrants [Member]
Derivative liability, beginning balance	181,381
Addition of new conversion option derivatives
Conversion of note derivatives
Changes in fair value	(166,137)
Derivative liability, ending balance	$ 15,244

Derivative Valuation - Schedu_2

Derivative Valuation - Schedule of Assumptions Used Black Scholes Valuation of Derivative (Details) - Derivative Liability [Member]	9 Months Ended
	Sep. 30, 2019$ / shares
Exercise price of warrants	$ .25
Conversion rate of convertible debt	$ 0.445
Valuation Technique, Option Pricing Model [Member] | Measurement Input, Expected Dividend Rate [Member]
Derivative liability, fair value measurement input percentages	0
Minimum [Member]
Stock price at valuation date	$ 0.03
Minimum [Member] | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Risk Free Interest Rate [Member]
Derivative liability, fair value measurement input percentages	1.6
Minimum [Member] | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Price Volatility [Member]
Derivative liability, fair value measurement input percentages	102.5
Minimum [Member] | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Expected Term [Member]
Derivative liability, term	22 days
Maximum [Member]
Stock price at valuation date	$ 0.10
Maximum [Member] | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Risk Free Interest Rate [Member]
Derivative liability, fair value measurement input percentages	2.42
Maximum [Member] | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Price Volatility [Member]
Derivative liability, fair value measurement input percentages	190
Maximum [Member] | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Expected Term [Member]
Derivative liability, term	2 years 8 months 19 days

Subsequent Events (Details Narr

Subsequent Events (Details Narrative)	Oct. 02, 2019USD ($)Integer	Nov. 14, 2019USD ($)shares	Jul. 31, 2018shares	Jun. 30, 2018USD ($)shares	Sep. 30, 2019USD ($)shares	Jun. 30, 2019USD ($)shares	Mar. 31, 2019USD ($)shares	Sep. 30, 2018USD ($)shares	Jun. 30, 2018USD ($)shares	Mar. 31, 2018USD ($)shares	Sep. 30, 2019USD ($)shares	Sep. 30, 2018USD ($)shares	Oct. 10, 2019shares	Jul. 09, 2019shares	Dec. 31, 2018shares
Common stock shares authorized | shares					1,900,000,000						1,900,000,000				1,900,000,000
Shares issued during period for consulting services, value					$ 152,572	$ 158,084	$ 181,549	$ 78,865	$ 112,100	$ 138,600
Shares issued for debt conversion					$ 531,425	$ 53,755	$ 347,487	$ 620,490	$ 636,706	$ 213,292
Consulting Agreement [Member]
Shares issued during period for consulting services, shares | shares			1,500,000	125,000
Common Stock [Member]
Common stock shares authorized | shares					900,000,000						900,000,000			400,000,000
Shares issued during period for consulting services, shares | shares					2,274,997	1,650,435	1,324,560	1,325,000	1,200,000	1,350,000
Shares issued during period for consulting services, value					$ 2,275	$ 1,650	$ 1,325	$ 1,325	$ 1,200	$ 1,350
Shares issued for debt conversion, shares | shares					13,991,743	1,181,433	5,097,255	12,943,900	13,708,947	3,945,407
Shares issued for debt conversion					$ 13,992	$ 1,181	$ 5,098	$ 12,944	$ 13,710	$ 3,945
Common Stock [Member] | Consulting Agreement [Member]
Shares issued during period for consulting services, shares | shares				1,500,000
Shares issued during period for consulting services, value				$ 105,000
Convertible Notes [Member]
Debt face amount					889,950						$ 889,950
Shares issued for debt conversion, shares | shares											20,270,431	26,598,252
Shares issued for debt conversion											$ 932,667	$ 1,190,189
Accrued interest					$ 40,217			$ 163,157			$ 40,217	$ 163,157
Subsequent Event [Member]
Common stock shares authorized | shares													1,900,000,000
Subsequent Event [Member] | Consulting Agreement [Member]
Shares issued during period for consulting services, shares | shares		374,999
Shares issued during period for consulting services, value		$ 12,150
Subsequent Event [Member] | Common Stock [Member]
Shares issued during period for consulting services, shares | shares		1,050,000
Shares issued during period for consulting services, value		$ 39,750
Subsequent Event [Member] | 10% Convertible Promissory Note [Member]
Debt face amount	$ 57,750
Debt maturity date	Oct. 2, 2020
Original issue discount	$ 5,250
Transaction costs	$ 2,500
Convertible debt percentage	65.00%
Number of trading days | Integer	20
Convertible notes, description	The convertible note converts into common stock of the Company at a conversion price equal to 65% of the lowest trading prices during the twenty (20) trading day period ending on the last complete trading day prior to the conversion date
Subsequent Event [Member] | Convertible Notes [Member]
Debt face amount		$ 436,906
Shares issued for debt conversion, shares | shares		45,502,112
Shares issued for debt conversion		$ 508,655
Accrued interest		69,199
Financing costs		$ 2,550